Research at Tufts CSDD

Helping drug developers, regulators, and policy makers improve efficiency by providing objective data on R&D practices and the current regulatory environment

CSDD Courses & Forums

Helping pharmaceutical and biotechnology professionals, regulators, and policy makers understand and succeed in the global marketplace by providing the most current information on the strategy, management, and science of pharmaceutical R&D

Tufts CSDD Subscription-Based Reports

Providing essential new information about key drug development issues

Commission a Research Project

Tufts CSDD conducts special commissioned and custom projects on a wide variety of topics identified by individual or multiple project sponsors

May 9, 2012

Drug Sponsors' Regulatory Experience Was Mixed During PDUFA IV

Learn More....

April 26, 2012

Drug Companies Are Looking to Shorten Time to Early Clinical Development

Learn More....

January-March 2012

First Quarter 2012, Volume 8, Issue 1

Learn More....

Mar. 6, 2012

Drugs to Treat CNS Diseases Take 35% Longer to Develop than Other Drugs

Learn More....

January 26, 2012

Drug Company Executives Are Expanding Their Use of Strategic Partnerships

Learn More....

Jan. 17, 2012

Tufts [CSDD] Establishes Workload and Utilization Benchmarks for Global Clinical Research Associates

Learn More....

January 5, 2012

Drug Companies Are Taking Steps to Improve R&D Productivity

Learn More....

Nov. 17, 2011

Tufts CSDD presents a Forum on the Impact of CER on Biopharmaceutical Innovation and Patient Access

Learn More....

Nov. 8, 2011

Number of Monoclonal Antibody Products in Development Continues to Increase

Learn More....

October-December2011

Fourth Quarter 2011, Vol. 7, Issue 4

Learn More....

October 6, 2011

Drug Companies Are Using Innovative Partnerships to Spur Development

Learn More....

Sept. 13, 2011

Majority of Clinical Trial Protocols Are Amended, But One-Third of Those Changes Are Avoidable

Learn More....

July-September 2011

Third Quarter 2011, Vol. 7, Issue 3

Learn More....

August 9, 2011

Management Implications of the Global Regulatory Environment

Learn More....

July 19, 2011

Lack of Clinically Useful Diagnostics Hinder Growth in Personalized Medicines

Learn More....

April-June 2011

Second Quarter 2011, Vol. 7, Issue 2

Learn More....

May 10, 2011

Biotech Drug Approvals in the U.S. Nearly Doubled in the Last Decade

Learn More....

April 26, 2011

Drug Developers Actively Improving Efficiency of Clinical Trials

Learn More....

March 2011

Tufts CSDD's official response to the recent Light & Warburton commentary

Learn More....

January-March 2011

First Quarter 2011, Vol. 7, Issue 1

Learn More....

March 8, 2011

U.S. Approvals of Supplemental Drug Indications Have Been Rising Steadily

Learn More....

January 27, 2011

Translational Science Expected to Play a Growing Role in Creating New Drugs

Learn More....

January 12, 2011

U.S. Healthcare Stakeholders Uncertain about Benefits of Risk Evaluation Program

Learn More....

January 5, 2011

Drug Developers Are Aggressively Changing the Way They Do R&D

Learn More....

July 10-11, 2012

Leadership for Drug Development Teams

This program is designed in collaboration with R&D leaders from every segment of the industry. The curriculum is based on specific challenges that hundreds of team leaders, program managers, and functional directors have described in real-life cases. Two-third of the course is devoted to hands-on casework, and one-third to interactive discussions with the faculty.

Learn More | Register

May 17, 2012

Academic-Industry Partnerships: Opportunities and Pitfalls

We invite you to join us on May 17th for our next Tufts CSDD Executive Forum roundtable, Academic-Industry Partnerships: Opportunities and Pitfalls. The Tufts CSDD Executive Forum is the only program of its kind. Quarterly roundtable discussions, held in a facilitated and interactive small-group format, offer industry senior executives an opportunity to share ideas and experiences in R&D strategy, management, and practice.

Learn More | Register

Tufts CSDD R&D Management Reports

Tufts CSDD R&D Management Reports highlight guest speakers' presentations, panel sessions, and ensuing discussions from the quarterly Tufts CSDD Executive Forum roundtables.

Learn More | Purchase

Tufts CSDD Impact Reports

Tufts CSDD Impact Reports summarize current original research from Tufts CSDD and present it in a concise, easy-to-read format. This bi-monthly publication - the only one of its kind - presents data, analyses, and insights on critical drug development and regulatory issues.

Learn More | Purchase

Tufts Center for the
Study of Drug Development

Tufts University
75 Kneeland Street
Suite 1100
Boston, MA 02111
USA

Phone: 617-636-2170
Fax: 617-636-2425
E-mail: csdd@tufts.edu

Tufts Center for the Study of Drug Development

Tufts University

Research at Tufts CSDD

CSDD Courses & Forums

Tufts CSDD Subscription-Based Reports

Commission a Research Project

Drug Sponsors' Regulatory Experience Was Mixed During PDUFA IV

Drug Companies Are Looking to Shorten Time to Early Clinical Development

First Quarter 2012, Volume 8, Issue 1

Drugs to Treat CNS Diseases Take 35% Longer to Develop than Other Drugs

Drug Company Executives Are Expanding Their Use of Strategic Partnerships

Tufts [CSDD] Establishes Workload and Utilization Benchmarks for Global Clinical Research Associates

Drug Companies Are Taking Steps to Improve R&D Productivity

Tufts CSDD presents a Forum on the Impact of CER on Biopharmaceutical Innovation and Patient Access

Number of Monoclonal Antibody Products in Development Continues to Increase

Fourth Quarter 2011, Vol. 7, Issue 4

Drug Companies Are Using Innovative Partnerships to Spur Development

Majority of Clinical Trial Protocols Are Amended, But One-Third of Those Changes Are Avoidable

Third Quarter 2011, Vol. 7, Issue 3

Management Implications of the Global Regulatory Environment

Lack of Clinically Useful Diagnostics Hinder Growth in Personalized Medicines

Second Quarter 2011, Vol. 7, Issue 2

Biotech Drug Approvals in the U.S. Nearly Doubled in the Last Decade

Drug Developers Actively Improving Efficiency of Clinical Trials

Tufts CSDD's official response to the recent Light & Warburton commentary

First Quarter 2011, Vol. 7, Issue 1

U.S. Approvals of Supplemental Drug Indications Have Been Rising Steadily

Translational Science Expected to Play a Growing Role in Creating New Drugs

U.S. Healthcare Stakeholders Uncertain about Benefits of Risk Evaluation Program

Drug Developers Are Aggressively Changing the Way They Do R&D

Leadership for Drug Development Teams

Academic-Industry Partnerships: Opportunities and Pitfalls

Tufts CSDD R&D Management Reports

Tufts CSDD Impact Reports

Tufts Center for the Study of Drug Development

Tufts Center for the
Study of Drug Development